PROFIL Institut fuer Stoffwechselforschung GmbH
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The site is exploring how metabolic conditions such as obesity and diabetes influence heart health, with trials aimed at testing new medicines that could lower cardiovascular risk factors and improve vascular function.
- Impact of weight‑loss agents on blood pressure and lipid profiles
- Evaluation of renal outcomes in patients with metabolic liver disease
- Assessment of insulin‑based therapies for cardiovascular safety
- Safety and tolerability of emerging metabolic drugs in at‑risk populations
PROFIL Institut fuer Stoffwechselforschung GmbH collaborates with commercial partners to generate data that may guide future cardiovascular prevention strategies.
Hormonal Diseases
Research at the centre focuses on disorders of hormone regulation, chiefly type 1 and type 2 diabetes, by evaluating novel insulin formulations and agents that modulate glucose metabolism.
- Comparative studies of new insulin analogues
- Investigation of GLP‑1 receptor agonists on glycaemic control
- Pharmacodynamic profiling of combination hormone therapies
- Safety monitoring of long‑term hormonal treatment in diabetic subjects
The trials aim to improve blood‑sugar management and reduce complications associated with hormonal imbalance.
Nutritional and Metabolic Diseases
The institute conducts studies on conditions linked to nutrition and metabolism, including obesity, overweight, and non‑alcoholic steatohepatitis (NASH), seeking therapies that promote weight loss and liver health.
- Evaluation of agents that reduce liver fat content
- Weight‑management interventions combined with lifestyle counseling
- Impact of metabolic drugs on metabolic syndrome components
- Safety and efficacy of novel compounds in obese participants
Findings are intended to support new treatment options for patients struggling with excess weight and related metabolic complications.
Metabolism
A broad spectrum of trials investigates fundamental aspects of human metabolism, such as glucose handling, insulin sensitivity, and renal function, using both healthy volunteers and patients with metabolic disorders.
- Glucose‑tolerance assessments after novel therapeutic exposure
- Pharmacokinetic and pharmacodynamic studies of metabolic agents
- Renal function monitoring in participants with suspected metabolic liver disease
- Bioequivalence testing of insulin products in controlled settings
These investigations help clarify how new drugs influence metabolic pathways and support the development of safer, more effective treatments.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
- 1Novo Nordisk A/S4active
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S13trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in PROFIL Institut fuer Stoffwechselforschung GmbH
lock Showing 1 of 39 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effect of Steady-State AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Type 2 Diabetes Mellitus | AstraZeneca AB | Phase I | Recruiting | Jul 2026 | — |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ascorbic Acid | 1 | Unknown | 2023-09-28 | 2023-09-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.